Rigin 200mg (Palmitoyl Tetrapeptide 7) (Topical)
Peptide Sciences
Topical Research PeptideCosmetic anti-ageing lipopeptide (Palmitoyl Tetrapeptide-7)
Certifications
- Supplied as a research Use Only (RUO) peptide and not approved by the FDA, EMA, MHRA or other regulatory agencies as a drug, cosmetic ingredient for commercial sale, or medical device.
- Manufactured and tested according to the supplier’s internal quality standards (e.g., ≥99% purity by HPLC) appropriate for research chemicals.
- Supplied as a research Use Only (RUO) peptide and not approved by the FDA, EMA, MHRA or other regulatory agencies as a drug, cosmetic ingredient for commercial sale, or medical device.
- Manufactured and tested according to the supplier’s internal quality standards (e.g., ≥99% purity by HPLC) appropriate for research chemicals.
Cosmetic anti-ageing lipopeptide (Palmitoyl Tetrapeptide-7)
Description
Rigin 200mg (Palmitoyl Tetrapeptide-7) (Topical) is a high-purity, research-grade cosmetic peptide supplied as a lyophilised powder for topical formulation and in-vitro studies. Rigin is the trade name commonly used for palmitoyl tetrapeptide-7, a lipopeptide with the sequence Pal-Gly-Gln-Pro-Arg (Pal-GQPR), originally developed to mimic part of the immunoglobulin G (IgG) molecule. In experimental models, palmitoyl tetrapeptide-7 has been investigated for its ability to modulate cytokine activity (especially interleukin-6), reduce inflammation, support extracellular matrix homeostasis and stimulate collagen and elastin synthesis in the skin. These properties make it of interest in anti-ageing and skin-repair research, where it may help improve firmness, elasticity, hydration and overall skin texture when incorporated into topical test formulations. This product contains 200 mg of palmitoyl tetrapeptide-7 at ≥99% purity (HPLC) and is labelled for research use only, not for human or veterinary use.
Bnefits
- Provides a defined, high-purity source of palmitoyl tetrapeptide-7 (Rigin) for cosmetic and dermatological research.
- Investigated for stimulating collagen and elastin synthesis, supporting improved skin firmness and elasticity in experimental systems.
- May help reduce the appearance of fine lines and wrinkles and improve overall skin smoothness in topical formulation studies.
- Shown in research models to modulate cytokine activity (e.g., IL-6), potentially reducing inflammation-related damage to the extracellular matrix.
- Associated with improved skin hydration, barrier support and smoother texture when formulated appropriately in test products.
- Lipid (palmitoyl) modification enhances peptide affinity for skin and potential penetration in topical research formulations.
- Supplied as a lyophilised powder at ≥99% HPLC purity for reproducible formulation and in-vitro work.
- Research-use-only labelling supports safe, controlled use in non-clinical environments.
Indications
- In-vitro and ex-vivo research on skin ageing, inflammation and extracellular matrix regulation.
- Development and testing of experimental topical cosmetic formulations targeting wrinkles, firmness and elasticity.
- Studies on modulation of cytokines (particularly IL-6) and matrix metalloproteinases (MMPs) in skin models.
- Combination studies with other cosmetic peptides (e.g., palmitoyl tripeptide-1, Matrixyl 3000 components) to explore synergistic anti-ageing effects.
- Not indicated or approved for direct therapeutic use in humans or animals.
Composition
- Active ingredient: Palmitoyl Tetrapeptide-7 (Rigin), sequence Pal-Gly-Gln-Pro-Arg (Pal-GQPR).
- Molecular formula: C34H62N8O7.
- CAS number: 221227-05-0.
- Molecular weight: approximately 694.9 g/mol (palmitoylated peptide).
- Purity: ≥99% (HPLC), research grade.
- Supplied as lyophilised peptide powder without added excipients (carrier-free), unless otherwise specified on the vial label.
Formulation
- Physical form: White to off-white lyophilised powder.
- Chemical class: Lipo-tetrapeptide (palmitoylated peptide) derived from an IgG fragment.
- INCI/trade names commonly associated: Palmitoyl Tetrapeptide-7, Rigin™, N-Palmitoylrigin, Pal-GQPR.
- Intended route in research: Topical (for incorporation into experimental creams, serums or gels) and in-vitro test systems.
- Typical reconstitution in research: Dissolved in sterile water, buffer or suitable cosmetic solvent phase prior to dilution into final test vehicles (exact conditions determined by the researcher).
Packaging
- Standard presentation: 1 x 200 mg vial of lyophilised palmitoyl tetrapeptide-7 powder.
- Vial type: Sealed laboratory vial suitable for peptide storage (material and closure specification per supplier).
- Primary container labelled with product name (Rigin – Palmitoyl Tetrapeptide-7), amount (200 mg), purity (99% HPLC), CAS number, molecular formula and research-use-only warnings.
- Outer packaging: Protective shipping materials to maintain temperature and protect the vial during transit.
Usage
- For laboratory research and in-vitro use only; not for human or veterinary use and not for use in finished consumer products without appropriate regulatory clearance.
- Allow the vial to reach room temperature before opening to minimise condensation.
- Reconstitute the lyophilised powder using a suitable sterile solvent (e.g., sterile water, buffer or relevant cosmetic phase) according to the requirements of the specific study or formulation; mix gently until fully dissolved.
- Prepare working dilutions immediately prior to use to minimise peptide degradation; avoid vigorous shaking or foaming.
- When formulating into experimental topical vehicles, ensure compatibility with other ingredients (pH, solvent system, preservatives) and protect from excessive heat and light.
- Use appropriate aseptic technique and personal protective equipment (PPE) when handling the peptide and any solutions.
- Do not inject, ingest or apply directly to humans or animals; all work should comply with institutional safety and ethical guidelines.
- Dispose of any unused solutions and materials following local regulations for chemical and biological laboratory waste.
Contraindications
- Not for human or veterinary use; must not be injected, ingested, or applied directly to living subjects.
- Use is contraindicated outside controlled research settings (e.g., home or cosmetic self-use is not permitted).
- Do not use if vial, seal or label is damaged, missing or shows signs of tampering.
- Researchers with known hypersensitivity to peptide powders or laboratory chemicals should use caution and appropriate PPE.
- Not to be combined with other substances in ways that contravene local safety, chemical or biosafety regulations.
Adverse Effects
- No clinical adverse-effect profile is established, as the product is not intended or approved for clinical use.
- Laboratory handling risks include potential irritation from dust or aerosols if mishandled; avoid inhalation, ingestion or contact with skin and eyes.
- Spills or splashes may cause transient irritation and should be managed with standard laboratory first-aid and decontamination procedures.
- Improper storage or handling may lead to peptide degradation, loss of activity or formation of breakdown products, which could affect experimental results.
Storage Conditions
- Store lyophilised peptide at approximately −20 °C in a dry, dark environment.
- Keep vial tightly closed and protected from moisture, heat and direct light.
- Allow vial to reach room temperature before opening to reduce condensation risk.
- After reconstitution, store solutions at 2–8 °C for short-term use or aliquot and freeze at −20 °C or below for longer-term storage, as compatible with the specific solvent system.
- Avoid repeated freeze–thaw cycles by preparing single-use aliquots where possible.
- Always follow any additional storage information provided on the product label or certificate of analysis.
Duration
Not applicable as a finished treatment; duration of exposure or application is defined by the specific research protocol or in-vitro assay design.
Onset
In experimental models, changes in cytokine expression, extracellular matrix markers or skin-related endpoints are typically assessed over hours to weeks, depending on the assay and formulation; no clinically defined onset of effect exists for this research-only product.
